Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations were $-2.92. Operator: Good day, and thank you for standing by. Welcome to ...

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a ...

Despite a significant revenue drop, Moderna Inc (MRNA) focuses on financial discipline and pipeline growth to drive future ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLavina Talukdar - Senior Vice President, ...